JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
Tel: +1-832-696-8203
Email: [email protected]
Worldwide Distributors
In vitro transcription of capped mRNA with modified nucleotides and Poly(A) tail
TSA (Tyramide Signal Amplification), used for signal amplification of ISH, IHC and IC etc.
Separation of phosphorylated and non-phosphorylated proteins without phospho-specific antibody
A convenient and sensitive way for cell proliferation assay and cytotoxicity assay
Protect the integrity of proteins from multiple proteases and phosphatases for different applications.
MK-0591, an analog of MK-886 is a potent and orally active leukotriene biosynthesis inhibitor with an IC50 value of 600 ng/ml. MK-0591(250 mg) nearly completely inhibited systemic leukotriene synthesis (>90%) in whole blood or in patients with active disease, and induced LTB4 synthesis in the target tissue of inflammation. [1]MK-0591 plays as a potential agent for the treatment of asthma and inflammatory bowel disease. MK-0591 specific interacted with 5-lipoxygenase, a membrane protein activating protein FLAP, which is essential for LT synthesis in inflammatory cells. [3]MK-0591 inhibited 96% production of LTB4 in whole blood and 91% that from BAL cells. By contrast, MK-0591 had no effect on airway hyper-responsiveness, ozone-induced bronchoconstriction, or influx of neutrophils into BAL. [4]References:1.Hillingsø J, Kjeldsen J, Laursen LS et al. Blockade of leukotriene production by a single oral dose of MK-0591 in active ulcerative colitis. Clin Pharmacol Ther. 1995 Mar;57(3):335-41.2.Prasit P, Belley M, Blouin M et al. A new class of leukotriene biosynthesis inhibitor: the development of MK-0591. J Lipid Mediat. 1993 Mar-Apr;6(1-3):239-44.3.Stevens WH, Lane CG, Woolley MJ et al. Effect of FLAP antagonist MK-0591 on leukotriene production and ozone-induced airway responses in dogs. J Appl Physiol (1985). 1994 Apr;76(4):1583-8.